secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001104659-25-001666
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute (RZLT) gets FDA Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation to ersodetug (RZ358) for hypoglycemia due to congenital hyperinsulinism.
- Designation based on Phase 2b (RIZE) study: ≥75% reduction in hypoglycemia, no clinically significant hyperglycemia.
- Topline results from Phase 3 sunRIZE study expected H2 2025; U.S. sites enrolling after partial clinical hold lifted.
- Company raised $73M in June 2024, extending cash runway into Q2 2026 to support clinical programs.
- Also received ODD and IND clearance for tumor HI Phase 3 study, with topline results expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925001666/0001104659-25-001666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925001666/tm252102d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer